Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BUFFALO, NY--(Marketwire - March 9, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Roth Capital Partners 22nd Annual OC Growth...
-
BUFFALO, NY--(Marketwire - March 4, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will hold its 2010 annual stockholders meeting on June 8, 2010 in Buffalo, NY...
-
BUFFALO, NY--(Marketwire - February 26, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) (the "Company") announced today that it has signed an agreement with various institutional investors for...
-
BUFFALO, NY--(Marketwire - February 24, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has submitted a response to the Request for Proposal (RFP) issued by The Department of...
-
BUFFALO, N.Y., Feb. 24, 2010 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that it has submitted a response to the Request for Proposal (RFP) issued by The Department of...
-
BUFFALO, N.Y., Feb. 22, 2010 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI), an innovator of drugs for treatment of cancer and protection of normal tissues from exposure to radiation, is...
-
BUFFALO, N.Y., Feb. 17, 2010 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI), an innovator of drugs for treatment of cancer and protection of normal tissues from exposure to radiation, is...
-
BUFFALO, NY--(Marketwire - January 28, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that the European Patent Office (EPO) has granted its European Patent Application Number...
-
BUFFALO, NY--(Marketwire - January 27, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 2010 BIO CEO & Investor Conference, February...
-
BUFFALO, NY--(Marketwire - January 19, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the first healthy volunteers have been dosed in the second human safety study for CBLB502, a...